Cantargia's IPO

Cantargia raised a round of funding on September 25, 2018. Investors include Public.

Cantargia is a biotech company specialized in antibody-based cancer treatment. CAN04 (nidanilimab), the company's main project and patented antibody treatment in clinical development, has a dual mecha…

Articles about Cantargia's IPO: